| Autor: |
Maria Lucia Marino, Alessandro C. Rosa, Marco Finocchietti, Arianna Bellini, Francesca R. Poggi, Marco Massari, Stefania Spila Alegiani, Lucia Masiero, Andrea Ricci, Gaia Bedeschi, Francesca Puoti, Massimo Cardillo, Silvia Pierobon, Maurizio Nordio, Eliana Ferroni, Martina Zanforlini, Giuseppe Piccolo, Olivia Leoni, Stefano Ledda, Paolo Carta, Donatella Garau, Ersilia Lucenteforte, Marina Davoli, Antonio Addis, Valeria Belleudi |
| Rok vydání: |
2023 |
| Zdroj: |
Frontiers in Transplantation. 1 |
| ISSN: |
2813-2440 |
| DOI: |
10.3389/frtra.2022.1060621 |
| Popis: |
BackgroundIn immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (CNI: tacrolimus-TAC or cyclosporine-CsA), antimetabolites (antiMs), mammalian target of rapamycin inhibitors (mTORis), and corticosteroids. However, data on immunosuppressive therapy by organ and its space–time variability are lacking.MethodsAn Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009–2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year.ResultsThe most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used.ConclusionA high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk–benefit profile of treatment schemes adopted in clinical practice. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
